Literature DB >> 15960150

Poststreptococcal acute glomerulonephritis superimposed on bilateral renal hypoplasia.

Y Naito-Yoshida1, Y Naico-Yoshida, M Hida, Y Maruyama, N Hori, M Awazu.   

Abstract

An 8-year-old girl with preexisting chronic renal failure (CRF) due to bilateral renal hypoplasia presented with edema, gross hematuria and acute deterioration of renal function. The diagnosis of poststreptococcal acute glomerulonephritis (PSAGN) was made based on clinical presentation, red blood cell casts, low level of C3 and elevated antistreptolysin 0 titer. Her course was prolonged with serum creatinine increased from the baseline level of 1.1 mg/dl to 2.2 mg/dl, returning toward the baseline level (1.2 mg/dl) after one month. Serum creatinine then started to increase again. The slope of creatinine clearance over time became steeper after the episode of PSAGN. A severe course of PSAGN and subsequent deterioration of renal function have previously been reported in patients with diabetic nephropathy or focal glomerulosclerosis. The present case along with a literature review suggests that individuals with fewer nephrons are at higher risk of severe course and outcome of PSAGN. Conversely, patients with severe PSAGN may be born with fewer nephrons due to low birth weight, unrecognized renal hypoplasia or other unknown causes.

Entities:  

Mesh:

Year:  2005        PMID: 15960150     DOI: 10.5414/cnp63477

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  2 in total

1.  Poststreptococcal acute glomerulonephritis can be a risk factor for accelerating kidney dysfunction in Alport syndrome: a case experience.

Authors:  Yoshinori Araki; Azusa Kawaguchi; Nana Sakakibara; Yoshinobu Nagaoka; Tomohiko Yamamura; Tomoko Horinouchi; China Nagano; Naoya Morisada; Kazumoto Iijima; Kandai Nozu
Journal:  CEN Case Rep       Date:  2020-06-26

2.  The implications of fetal programming of glomerular number and renal function.

Authors:  Jörg Dötsch; Christian Plank; Kerstin Amann; Julie Ingelfinger
Journal:  J Mol Med (Berl)       Date:  2009-08-04       Impact factor: 4.599

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.